Genmab — Maj 2018
-
Jeg tror gerne at Børsen (og alle andre) vil have en direkte udtalelse fra JDW
-
Er det ikke nu man skal købe?
-
Virker til et røverkøb?
-
Jeg har lige overført alt hvad jeg har af overskudende penge fra netbank til NN. Så nu må den strakoverførsel godt gå igennem asap, så jeg kan få del i dette røverkøb.
-
Løntoft er nu ganske fornuftig at høre på: https://play.borsen.dk/klip/5b0b970a45628ff8172242a1/genmab-analytiker_om_aktiestyrt_panik_paa_boersen_-_nu_skal_du_koebe.html
-
898 i børnes depot.
-
Ser ud til at tossetimen er ved at være ovre. Jeg tror også den langsomt kommer tilbage over 1200 om 3-5 måneder.
-
sowise...Jeg forstår slet ikke hvad du mener?
-
Hvilken "betydning" mener du, at Genmab bør have meldt ud?
-
Hermed kommentar fra Bowers: MM spill over. We do not see any material negative spill over to the Multiple Myeloma (MM) indications from which we still project more than USD9bn in peak sales. However, the increased mortality-related events in the study does, in our view, make Darzalex as a back-bone MM therapy potentially more vulnerable as the PD-1/PD-L1 combination option right now is gone - at least until the possible safety issues with the combination have been fully elucidated. We see PoC
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind